Dupilumab (open-label)    (DrugBank: Dupilumab)

1 disease
IDDisease name (Link within this page)Number of trials
98Eosinophilic gastrointestinal disease1

98. Eosinophilic gastrointestinal disease    [ 128 clinical trials,   147 drugs,   (DrugBank: 40 drugs),   34 drug target genes,   132 drug target pathways]
Searched query = "Eosinophilic gastrointestinal disease", "Eosinophilic gastroenteritis", "Eosinophilic esophagitis", "Eosinophilic colitis", "Eosinophilic gastro-intestinal disorder", "EGID", "Neonatal food-protein induced enterocolitis", "N-FPIES"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 128 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03678545
(ClinicalTrials.gov)
September 1, 20206/8/2018Dupilumab in Eosinophilic GastritisA Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy of Dupilumab (Anti-IL4a) in Subjects With Eosinophilic GastritisEosinophilic Gastritis;Eosinophilic GastroenteritisDrug: Dupilumab (blinded);Drug: Placebo (blinded);Drug: Dupilumab (open-label)Children's Hospital Medical Center, CincinnatiRegeneron PharmaceuticalsNot yet recruiting12 Years70 YearsAll40Phase 2United States